| Authors | Jackson, M.L. McEvoy, R.D. Banks, S. Barnes, M. |
|---|---|
| Type | Journal Article (Original Research) |
| Journal | Journal of Clinical Sleep Medicine |
| PubMed ID | 29198304 |
| Year of Publication | 2018 |
| URL | https://www.ncbi.nlm.nih.gov/pubmed/29198304 |
| DOI | /10.5664/jcsm.6878 |
| Abstract | STUDY OBJECTIVES: The degree of neurobehavioral impairment and treatment response in mild-moderate obstructive sleep apnea (OSA) compared to that of an appropriate control group are unclear. This study compared neurobehavioral function and response to continuous positive airway pressure (CPAP) treatment in patients with mild to moderate OSA with those of a non-sleep apneic community sample of similar demography. METHODS: One hundred ten patients with OSA and 31 asymptomatic community dwellers underwent overnight polysomnography and neurobehavioral testing. Participants with OSA (n = 88) were treated with CPAP for 3 months, and repeat evaluations were performed at the end of the treatment period. RESULTS: Compared to the community sample, participants with OSA were significantly sleepier, had impaired mood and quality of life, and showed decrements in neuropsychological function, specifically psychomotor function, working memory and vigilance. Some neuropsychological and mood outcomes were normalized with CPAP, but significant decrements persisted in most outcomes even in those participants with adequate device usage. CONCLUSIONS: Patients with mild to moderate OSA have significant neurobehavioral morbidity. During "gold standard" treatment, normal function was not achieved, even with adequate device usage. CPAP efficacy for improving sleepiness and neuropsychological function in this milder end of the OSA spectrum may be poor, which may affect CPAP adherence. These findings suggest that there may be neurological changes related to OSA that do not respond to CPAP treatment, the etiology of which requires further investigation. |
http://www.ibas.org.au/what-we-do/publications/3872970
Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...
RESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE
The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...
Motor neurone disease (MND) causes the body's muscles to weaken. Breathing muscle weakness means that most people affected by MND will eventually lose the ability to take a deep breath and cough strongly....
ResearchFest 2026 at Austin Health launched new research flagships and honored Professor Mark Howard (Distinguished Scientist) and Professor Eliza Hawkes (Women in Research Award), with insights from Peter Doherty.
We are announcing exciting updates to our Early and Mid-Career Researcher (EMCR) representation at the Institute for Breathing and Sleep (IBAS). The MSRC extend a warm thank you to Charissa Zaga and welcome Jessica Manousakis!
ANZSRS LIFE MEMBERSHIP FOR DANNY BRAZZALE
Danny Brazzale has earned a prestigious ANZSRS Life Membership—held by only 11 people—for his global leadership and dedicated mentorship in respiratory science.
PERTH HIGHLIGHTS: TSANZSRS 2026
A huge congratulations to all our team members who participated in the excellent workshops and meetings at the TSANZSRS Annual Scientific Meeting in Perth in March 2026! Well Done!
© 2026 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
